Welcome to our dedicated page for Albemarle SEC filings (Ticker: ALB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Albemarle Corporation (NYSE: ALB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Virginia-incorporated public company with common stock listed on the NYSE, Albemarle regularly submits reports that cover financial results, material agreements, governance updates and other significant events.
Among the key documents are Form 8-K current reports, where Albemarle discloses items such as quarterly earnings releases, material definitive agreements, goodwill impairment conclusions, director and officer changes, and organizational structure updates. For example, recent 8-K filings have described the company’s third quarter results, the stock purchase agreement related to the sale of a controlling stake in Ketjen’s refining catalyst solutions business, the planned sale of its interest in the Eurecat joint venture, and changes in senior leadership roles.
Investors can also use this page to locate references to Albemarle’s use of proceeds from portfolio transactions, its assessment of impairment charges, and its classification of certain businesses as held for sale. These filings help explain how Albemarle manages its lithium, bromine and catalyst-related operations within its broader financial and strategic framework.
Stock Titan enhances access to Albemarle’s filings by pairing real-time updates from EDGAR with AI-powered summaries that highlight the main points of lengthy documents. Users can quickly understand the implications of new 8-Ks, as well as the content of other core filings such as annual and quarterly reports, and can review disclosures related to executive arrangements and board changes without reading every line of the original text.
Albemarle Corporation reported that senior vice president Cynthia Renee Lima received an equity award of 1,796 shares of common stock as a grant or other acquisition. The award was priced at $0.00 per share, increasing her directly held stake to 14,438 shares. According to the terms, these restricted stock units vest 100% on March 2, 2029, tying a portion of her compensation to the company’s long-term performance.
Albemarle Corporation filed an update describing changes to its Board of Directors. Effective February 26, 2026, the Board appointed Michelle T. Collins and Mark R. Widmar as independent directors. Collins joined the Audit & Finance and Governance & Public Policy Committees, while Widmar joined the Executive Compensation & Talent Development and Safety, Sustainability, Operations & Capital Committees.
Under Albemarle’s non-employee director compensation program, each new director will receive an annual cash retainer of $120,000, paid quarterly and prorated for their partial initial term, plus an annual grant of restricted stock valued at $170,000, rounded to the nearest 25 shares and prorated for the partial year. The company states there are no special arrangements behind their selection and no related-party transactions requiring disclosure. A press release dated March 2, 2026, further announcing these appointments is furnished as an exhibit.
Albemarle Corporation’s Chief Commercial Officer Eric Norris reported equity compensation activity involving company common stock. He acquired 1,806 shares on February 26, 2026 at $184.93 per share through the vesting of previously granted Performance Stock Units, bringing his direct holdings to 49,738 shares.
On the same date, 785 shares at $184.93 per share were disposed of to cover tax liabilities tied to the 2023 Performance Stock Unit grant vesting. After this tax-withholding disposition, Norris held 48,953 shares of Albemarle common stock directly.
Albemarle Corp executive Mark Richard Mummert reported equity award activity involving company common stock. On February 26, 2026, he acquired 366 shares at $184.93 per share through a grant/award tied to Performance Stock Units originally granted on February 24, 2023. The footnotes explain that these units were split between ROIC and rTSR Performance Stock Units and that all shares earned vested on February 26, 2026. On the same date, 159 shares at $184.93 per share were disposed of to cover tax liabilities associated with this vesting. Following these transactions, he held 14,372 shares of Albemarle common stock directly.
Albemarle Corp executive Melissa H. Anderson reported equity compensation activity involving the company’s common stock. On February 26, 2026, she acquired 1,129 shares through the vesting of Performance Stock Units that were originally granted on February 24, 2023, split between ROIC and rTSR performance awards.
On the same date, 491 shares were disposed of to cover tax liabilities related to this vesting, as a tax-withholding disposition rather than an open‑market sale. After these transactions, she directly owned 9,512 shares of Albemarle common stock and also indirectly held 179.1617 shares through the Albemarle Savings Plan as of this Form 4.
Albemarle Corporation senior vice president Cynthia Renee Lima reported equity compensation activity involving company common stock. On 02/26/2026, she acquired 147 shares at $184.93 per share through the vesting of Performance Stock Units that were originally granted on 02/24/2023.
According to the disclosure, 50% of those Performance Stock Units were based on ROIC performance and 50% on relative total shareholder return, and all shares earned vested on 02/26/2026. On the same date, 64 shares at $184.93 per share were disposed of to cover tax liabilities associated with the vesting, leaving her with 12,642 directly owned shares after these transactions.
Albemarle Corp General Counsel & Secretary Ander C. Krupa reported equity compensation activity involving common stock. On 2/26/2026, she acquired 173 shares at $184.93 per share through a grant or award tied to Performance Stock Units granted on 2/24/2023. On the same date, 80 shares at $184.93 per share were disposed of to satisfy tax liabilities related to the vesting of those units. After these transactions, she directly owned 11,388 common shares.
Albemarle Corp Chief People Officer Autumn M. Gagarinas reported equity compensation activity involving common stock. She acquired 194 shares on February 26, 2026 as a grant tied to Performance Stock Units granted on February 24, 2023, when all earned shares vested. On the same date, 85 shares were disposed of through a tax-withholding transaction to cover liabilities from that vesting. After these transactions, she directly owned 3,597 common shares.
Albemarle Corporation director Mark R. Widmar reported receiving a grant of 325 Phantom Stock units on February 26, 2026. These units convert on a one-for-one basis into Albemarle common stock and are payable as shares upon events established under the company’s 2023 Directors Plan.
The Phantom Stock units have no expiration date. This grant represents a pro‑rata portion of his annual non‑employee director stock compensation under Albemarle’s 2023 Stock Compensation and Deferral Election Plan for Non‑Employee Directors, and the shares are scheduled to vest on July 1, 2026.
Albemarle Corporation executive Donald J. LaBauve Jr., VP, Corporate Controller & CAO, reported stock-based compensation activity in common stock. He received grants or vesting-related acquisitions of 1,266 shares on February 27, 2026 and 219 shares on February 26, 2026.
The filing also shows 361 shares and 67 shares were disposed of on those dates solely to cover tax liabilities tied to restricted stock unit vesting. In addition, 12,755 shares are held indirectly in the Albemarle Savings Plan as of the Form 4 date.